{"id":"abt-288-high-dose","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL3545029","moleculeType":"Small molecule","molecularWeight":"372.47"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Glucagon receptor antagonists are a class of drugs that block the action of glucagon, a hormone that raises blood glucose levels. By blocking glucagon, ABT-288 High Dose is expected to lower blood glucose levels and improve glycemic control in patients with diabetes.","oneSentence":"ABT-288 High Dose is a glucagon receptor antagonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:28:26.804Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT01077700","phase":"PHASE2","title":"Efficacy and Safety Study for Cognitive Deficits in Adult Subjects With Schizophrenia","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-03","conditions":"Cognitive Deficits in Schizophrenia","enrollment":214},{"nctId":"NCT01018875","phase":"PHASE2","title":"Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2009-12","conditions":"Alzheimer's Disease","enrollment":242}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ABT-288 High Dose","genericName":"ABT-288 High Dose","companyName":"AbbVie (prior sponsor, Abbott)","companyId":"abbvie-prior-sponsor-abbott","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ABT-288 High Dose is a glucagon receptor antagonist. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}